{"id":66864,"date":"2025-04-21T12:01:12","date_gmt":"2025-04-21T12:01:12","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/04\/21\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/"},"modified":"2025-04-21T12:01:12","modified_gmt":"2025-04-21T12:01:12","slug":"rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/","title":{"rendered":"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension"},"content":{"rendered":"<div>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SHANGHAI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 21, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for\u00a0<b>RN1871<\/b>, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved by <span class=\"xn-location\">China&#8217;s<\/span> National Medical Products Administration (NMPA).<\/p>\n<p>RN1871 is designed to silence AGT mRNA expression in the liver, precisely inhibiting the production of the key precursor protein in the Renin-Angiotensin-Aldosterone System (RAAS). The RAAS pathway plays a key role in blood pressure regulation, and its overactivation is closely linked to the progression of hypertension. Preclinical studies have demonstrated that RN1871 delivers long-lasting blood pressure control offering a promising new therapeutic option for over\u00a0<b>1.5 billion hypertension patients worldwide<\/b>.<\/p>\n<p><b><span class=\"xn-person\">Stella Shi<\/span>, CEO and Founder of Rona Therapeutics<\/b>, stated:\u00a0<i>&#8220;The IND approval of RN1871 marks a significant breakthrough in our pursuit of innovative therapies for chronic diseases. By leveraging siRNA technology to treat disease fundamentally, RN1871 achieves sustained efficacy with less dosing frequency. We look forward to bringing this innovative therapy to hypertension management where more compliant and safe treatment is needed to improve cardiovascular events and other comorbidities.&#8221; <\/i><\/p>\n<p><b>Dr. <span class=\"xn-person\">Alex M. DePaoli<\/span>, Chief Medical Officer and Executive Vice President of Translational Medicine<\/b>, added:\u00a0<i>&#8220;RN1871&#8217;s preclinical data showed potent AGT suppression which reduces blood pressure significantly with a favorable safety profile. We plan to advance RN1871 into Phase I trials to evaluate its safety, pharmacokinetics, and preliminary efficacy in humans. This progress reflects our team&#8217;s expertise in translating scientific insights into clinical solutions.&#8221;<\/i><\/p>\n<p><b>About Rona Therapeutics<br \/><\/b>Rona Therapeutics is a global leader in nucleic acid therapeutics discovery and development, specializing in the treatment of cardiometabolic and neurological diseases. Rona Therapeutics is committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, MASH and neurological diseases through both hepatic and extra-hepatic delivery of proprietary siRNA.<\/p>\n<p>For Further information,Please visit:\u00a0<a href=\"https:\/\/www.ronatherapeutics.com\/\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.ronatherapeutics.com<\/a>\u00a0or contact:\u00a0<a href=\"mailto:BD@ronatherapeutics.com\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">BD@ronatherapeutics.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, April 21, 2025 \/PRNewswire\/ &#8212;\u00a0Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for\u00a0RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved by China&#8217;s National Medical Products Administration (NMPA). RN1871 is designed to silence AGT mRNA expression in the liver, precisely inhibiting [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-66864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, April 21, 2025 \/PRNewswire\/ &#8212;\u00a0Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-21T12:01:12+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension\",\"datePublished\":\"2025-04-21T12:01:12+00:00\",\"dateModified\":\"2025-04-21T12:01:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/\"},\"wordCount\":345,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/\",\"name\":\"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-04-21T12:01:12+00:00\",\"dateModified\":\"2025-04-21T12:01:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/","og_locale":"en_US","og_type":"article","og_title":"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension","og_description":"SHANGHAI, April 21, 2025 \/PRNewswire\/ &#8212;\u00a0Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that","og_url":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-04-21T12:01:12+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension","datePublished":"2025-04-21T12:01:12+00:00","dateModified":"2025-04-21T12:01:12+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/"},"wordCount":345,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/","url":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/","name":"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-04-21T12:01:12+00:00","dateModified":"2025-04-21T12:01:12+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/66864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=66864"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/66864\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=66864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=66864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=66864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}